Nov 05, 2020
FDA nods Boston Scientific's paclitaxel-coated Ranger balloon for peripheral artery disease Boston Scientific has received the FDA approval for its Ranger paclitaxel-coated balloon, designed to restrict a patient's systemic exposure to the chemotherapy used to reduce the closure of reopened arteries. The slim...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper